EA200500849A1 - Новые соединения лапахона и способы их применения - Google Patents
Новые соединения лапахона и способы их примененияInfo
- Publication number
- EA200500849A1 EA200500849A1 EA200500849A EA200500849A EA200500849A1 EA 200500849 A1 EA200500849 A1 EA 200500849A1 EA 200500849 A EA200500849 A EA 200500849A EA 200500849 A EA200500849 A EA 200500849A EA 200500849 A1 EA200500849 A1 EA 200500849A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methods
- lapakhona
- application
- new connections
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000006994 Precancerous Conditions Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- QZPQTZZNNJUOLS-UHFFFAOYSA-N beta-lapachone Chemical class C12=CC=CC=C2C(=O)C(=O)C2=C1OC(C)(C)CC2 QZPQTZZNNJUOLS-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D335/08—Naphthothiopyrans; Hydrogenated naphthothiopyrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/92—Naphthofurans; Hydrogenated naphthofurans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/92—Naphthopyrans; Hydrogenated naphthopyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
- C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
- C07D327/06—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/74—Naphthothiophenes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42728302P | 2002-11-18 | 2002-11-18 | |
| PCT/US2003/022631 WO2004007531A2 (en) | 2002-07-17 | 2003-07-17 | Activated checkpoint therapy and methods of use thereof |
| US10/622,854 US20040209942A1 (en) | 2002-07-17 | 2003-07-17 | Activated checkpoint therapy and methods of use thereof |
| PCT/US2003/037219 WO2004045557A2 (en) | 2002-11-18 | 2003-11-18 | Novel lapachone compounds and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA200500849A1 true EA200500849A1 (ru) | 2006-02-24 |
Family
ID=34375156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200500849A EA200500849A1 (ru) | 2002-11-18 | 2003-11-18 | Новые соединения лапахона и способы их применения |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20040266857A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1567515A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2006508147A (cg-RX-API-DMAC7.html) |
| CN (1) | CN1729183A (cg-RX-API-DMAC7.html) |
| AR (1) | AR056613A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003295738A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR0316296A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2506340A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA200500849A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA05005314A (cg-RX-API-DMAC7.html) |
| TW (1) | TW200510367A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004045557A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7361691B2 (en) | 2002-12-02 | 2008-04-22 | Arqule, Inc. | Method of treating cancers using β-lapachone or analogs or derivatives thereof |
| WO2005053682A2 (en) | 2003-11-26 | 2005-06-16 | Arqule, Inc. | Use of beta-lapachone for protecting against radiation injury |
| WO2005082355A2 (en) * | 2004-02-20 | 2005-09-09 | Arqule, Inc. | Use of beta-lapachone for treatment of colon cancer |
| US20050187288A1 (en) * | 2004-02-20 | 2005-08-25 | Chiang Li | Beta-lapachone and methods of treating cancer |
| CA2556794A1 (en) * | 2004-02-20 | 2005-09-09 | Arqule, Inc. | Use of beta-lapachone as a broad spectrum anti-cancer agent |
| WO2005082353A2 (en) * | 2004-02-20 | 2005-09-09 | Arqule, Inc. | Use of beta-lapachone for treating or preventing cancer |
| CA2555950A1 (en) | 2004-02-20 | 2005-09-09 | Arqule, Inc. | Use of beta-lapachone for the treatment of pancreatic cancer |
| CA2556823A1 (en) * | 2004-02-20 | 2005-09-09 | Arqule, Inc. | Use of beta-lapachone for the treatment of lung cancer |
| JP2007523191A (ja) * | 2004-02-20 | 2007-08-16 | アークル・インコーポレーテツド | 血液腫瘍の治療のためのβ−ラパコンの使用 |
| WO2006020719A2 (en) | 2004-08-11 | 2006-02-23 | Arqule, Inc. | Aminoacid conjugates of beta - lapachone for tumor targeting |
| US8614228B2 (en) | 2004-08-11 | 2013-12-24 | Arqule, Inc. | Quinone prodrug compositions and methods of use |
| WO2006078503A2 (en) | 2005-01-07 | 2006-07-27 | Arqule, Inc. | Compositions for modulation of parp and methods for screening for same |
| WO2006128120A2 (en) * | 2005-05-26 | 2006-11-30 | Arqule, Inc. | Novel lapachone compounds and methods of use thereof |
| JP2009538298A (ja) * | 2006-05-26 | 2009-11-05 | アークル インコーポレイテッド | 新規のラパコン化合物およびその使用方法 |
| TW200824692A (en) | 2006-08-21 | 2008-06-16 | Arqule Inc | Novel lapachone compounds and methods of use thereof |
| EP2137168B1 (en) * | 2007-03-16 | 2016-09-14 | Lankenau Institute for Medical Research | Novel ido inhibitors and methods of use thereof |
| BRPI0810717A2 (pt) | 2007-04-30 | 2016-05-24 | Arqule Inc | sulfonato hidroxi de composto de quinona e seus usos |
| WO2009051752A1 (en) * | 2007-10-16 | 2009-04-23 | Arqule, Inc. | Novel lapachone compounds and methods of use thereof |
| KR101405823B1 (ko) * | 2007-12-24 | 2014-06-12 | 주식회사 케이티앤지생명과학 | 녹내장의 치료 및 예방을 위한 약제 조성물 |
| KR20090071829A (ko) * | 2007-12-28 | 2009-07-02 | 주식회사 머젠스 | 신장질환의 치료 및 예방을 위한 약제 조성물 |
| KR20090073381A (ko) * | 2007-12-31 | 2009-07-03 | 주식회사 머젠스 | 심장질환의 치료 및 예방을 위한 약제 조성물 |
| SG186129A1 (en) * | 2010-06-01 | 2013-01-30 | Belle Aire Fragrances Inc | Oral odor control method and product |
| WO2017106624A1 (en) | 2015-12-18 | 2017-06-22 | The Board Of Regents Of The University Of Texas System | Napthoquinones, pro-drugs, and methods of use thereof |
| KR101735275B1 (ko) * | 2016-12-20 | 2017-05-16 | 아주대학교산학협력단 | 베타-라파촌을 포함하는 수면 장애 예방 또는 치료용 조성물 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2011455B (en) * | 1977-12-21 | 1982-03-03 | Ici Ltd | Chemical process |
| US5346917A (en) * | 1991-06-10 | 1994-09-13 | Sterling Winthrop Inc. | Thioxanthenone antitumor agents |
| US5763625A (en) * | 1995-04-25 | 1998-06-09 | Wisconsin Alumni Research Foundation | Synthesis and use of β-lapachone analogs |
| US6245807B1 (en) * | 1995-08-24 | 2001-06-12 | Dana-Farber Cancer Institute | Treatment of human prostate disease |
| US5883270A (en) * | 1996-02-20 | 1999-03-16 | Wisconsin Alumni Research Foundation | 4-substituted-1, 2-naphthoquinones and their use in the inhibition of neoplastic cell growth |
| US5824700A (en) * | 1996-02-20 | 1998-10-20 | Wisconsin Alumni Research Foundation | Ortho-quinone derivatives novel synthesis therefor and their use in the inhibition of neoplastic cell growth |
| US20040209942A1 (en) * | 2002-07-17 | 2004-10-21 | Li Chiang J. | Activated checkpoint therapy and methods of use thereof |
| ES2273688T3 (es) * | 1999-04-14 | 2007-05-16 | Dana-Farber Cancer Institute, Inc. | Procedimiento y composicion para el tratamiento de cancer. |
-
2003
- 2003-11-18 JP JP2004553999A patent/JP2006508147A/ja active Pending
- 2003-11-18 BR BR0316296-6A patent/BR0316296A/pt not_active Application Discontinuation
- 2003-11-18 CN CNA2003801066171A patent/CN1729183A/zh active Pending
- 2003-11-18 EA EA200500849A patent/EA200500849A1/ru unknown
- 2003-11-18 TW TW092132328A patent/TW200510367A/zh unknown
- 2003-11-18 AR ARP030104253A patent/AR056613A1/es not_active Application Discontinuation
- 2003-11-18 AU AU2003295738A patent/AU2003295738A1/en not_active Abandoned
- 2003-11-18 CA CA002506340A patent/CA2506340A1/en not_active Abandoned
- 2003-11-18 EP EP03786941A patent/EP1567515A4/en active Pending
- 2003-11-18 MX MXPA05005314A patent/MXPA05005314A/es not_active Application Discontinuation
- 2003-11-18 WO PCT/US2003/037219 patent/WO2004045557A2/en not_active Ceased
-
2004
- 2004-03-26 US US10/810,260 patent/US20040266857A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AR056613A1 (es) | 2007-10-17 |
| MXPA05005314A (es) | 2005-10-19 |
| EP1567515A2 (en) | 2005-08-31 |
| JP2006508147A (ja) | 2006-03-09 |
| WO2004045557A3 (en) | 2004-08-12 |
| EP1567515A4 (en) | 2008-04-23 |
| WO2004045557A2 (en) | 2004-06-03 |
| CN1729183A (zh) | 2006-02-01 |
| BR0316296A (pt) | 2005-12-13 |
| AU2003295738A1 (en) | 2004-06-15 |
| US20040266857A1 (en) | 2004-12-30 |
| TW200510367A (en) | 2005-03-16 |
| CA2506340A1 (en) | 2004-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200500169A1 (ru) | Замещенные производные 1,3-дифенилпроп-2-ен-1-она, получение и применение | |
| EA200300171A1 (ru) | Циклопентаноиндолы, композиции, содержащие данные соединения, и способы лечения | |
| EA200400971A1 (ru) | Фторзамещенные циклоалканоиндолы, композиции, содержащие такие соединения, и способы лечения | |
| EA200200058A1 (ru) | Пиримидин-2,4,6-трионовые ингибиторы металлопротеиназ | |
| ATE433973T1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
| EA200100872A1 (ru) | Композиция валдекоксиба | |
| MXPA05005314A (es) | Compuestos de lapacona novedosos y metodos de uso de los mismos. | |
| EA200400595A1 (ru) | Бензимидазолы, применяемые в качестве ингибиторов протеинкиназы | |
| EA200500488A1 (ru) | Фармацевтические составы модафинила | |
| EA200401284A1 (ru) | Замещённые бензазолы и их применение в качестве ингибиторов киназы raf | |
| EA200401471A1 (ru) | Применение ингибиторов сетр и возможных ингибиторов hmg coa и/или антигипертензивных агентов | |
| EA200001224A1 (ru) | Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола | |
| DE60314603D1 (de) | Zusammensetzungen brauchbar als protein-kinase- inhibitoren | |
| ATE451376T1 (de) | Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen | |
| EA200300906A1 (ru) | Новые спиротрициклические производные и их применение в качестве ингибиторов фосфодиэстеразы-7 | |
| EA200000920A1 (ru) | Производные бициклических гидроксамовых кислот | |
| EA200300293A1 (ru) | Противовоспалительные конденсированные пирролокарбазолы | |
| EA200001223A1 (ru) | Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола | |
| EA200000911A1 (ru) | Новые кристаллические формы антивирусного соединения бензимидазола | |
| EA200300354A1 (ru) | Хинолиноновые производные в качестве ингибиторов тирозинкиназы | |
| EA200400648A1 (ru) | N, n'-замещенные производные 1,3-диамино-2-гидроксипропана | |
| BR0015416A (pt) | Composições contendo derivados do ácido hidroxieicosa tetraenóico e métodos de uso no tratamento de distúrbios de olhos secos | |
| EA200100127A1 (ru) | Производные фенилксантина | |
| EA199900421A1 (ru) | Бензонафтиридины в качестве бронхиальных терапевтических средств | |
| EA200500244A1 (ru) | Тетрапропиламмония тетратиомолибдат и родственные соединения для антиангиогенной терапии |